Skip to main content
Premium Trial:

Request an Annual Quote

Regulus, Biogen Idec Ink microRNA Collaboration for Multiple Sclerosis

NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

In exchange for its miRNA know how, Regulus will receive undisclosed upfront and milestone payments. Biogen Idec will also make an undisclosed investment in Regulus, which was formed in 2007 as a joint venture between RNAi firm Alnylam Pharmaceuticals and antisense drug developer Isis Pharmaceuticals.

Biogen Idec, which markets the multiple sclerosis drugs Tysabri, Avonex, and Fampyra, aims to use the biomarkers to select "optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse," Regulus said.

Further terms of the alliance were not disclosed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.